The new study, published in the Journal of Experimental & Clinical Cancer Research, focuses on the tumor microenvironment — the dense, inflammatory ecosystem that surrounds and permeates a tumor. Triple-negative breast cancer is notorious for heavy infiltration by myeloid immune cells, including tumor-associated macrophages. For years, these inflammatory macrophages have been statistically linked to poor outcomes, but the precise molecular choreography by which they drive malignant behavior has remained obscure. The Milan-led team, led by senior author Paola Falletta together with co-senior author Carlo Tacchetti, set out to close that gap, and in doing so identified a signaling axis that could become a therapeutic target in one of oncology’s hardest terrains.

The pathway at the center of the discovery is the Integrated Stress Response, or ISR, an ancient cellular circuit that acts as a molecular alarm system. When a cell perceives stress — nutrient deprivation, viral infection, or chemical insults — protein production in the endoplasmic reticulum stalls through phosphorylation of the translation initiation factor eIF2α, and the cell pivots from growth to survival mode, reprogramming gene expression to cope. Normally, this response protects cells. In cancer, however, tumor cells can hijack the ISR to survive hostile conditions, adopt invasive behaviors, and evade cell death. The new work shows that in triple-negative breast cancer, the stress being integrated is not only environmental — it is delivered by the immune system itself.

The researchers combined patient transcriptomic analyses, laboratory functional assays and in vivo metastasis models to build their case. First, mining breast cancer clinical cohorts, they found that gene-expression programs reflecting ISR activation are markedly enriched in triple-negative tumors compared with other breast cancer subtypes. Crucially, the enrichment was not random: high ISR signatures correlated with both poor patient outcomes and the presence of inflammatory macrophage infiltration. That correlation posed an obvious question — were the macrophages merely bystanders, or were they actively switching on the stress programs inside tumor cells?

To test causality, the team turned to controlled experiments in the laboratory. When triple-negative breast cancer cells were exposed to the secretome — the collected cocktail of secreted factors — from inflammatory macrophages, the tumor cells underwent a striking transformation. They activated their ISR circuitry and simultaneously acquired invasive capabilities, pushing through three-dimensional matrices in ways that untreated cells did not. Blocking the ISR pharmacologically or genetically prevented this invasion, demonstrating that the stress response was not a byproduct of the inflammatory exposure but a necessary engine of the invasive switch.

The hunt then turned to identifying which molecule within the macrophage secretion was responsible. Using an approach that combined unbiased screening with targeted validation, the researchers pinpointed CXCL10, a chemokine — a small signaling protein best known for recruiting immune cells to sites of inflammation. The result was remarkable in its completeness: CXCL10 alone was both necessary and sufficient to trigger ISR activation and invasion in the tumor cells. Its effects were mediated through its cognate receptor, CXCR3, displayed on the surface of the cancer cells. In other words, the team had mapped a complete paracrine circuit — macrophages release CXCL10, CXCL10 engages CXCR3 on tumor cells, and the engagement ignites the Integrated Stress Response, converting relatively dormant cancer cells into invasive, metastasis-competent ones.

The final and most demanding piece of evidence came from living systems. Using mouse models of metastatic dissemination, the investigators showed that tumor-intrinsic ISR signaling actively promotes the spread of triple-negative breast cancer in vivo. When the pathway was disrupted, metastatic colonization was impaired. Together, the clinical correlation, the mechanistic dissection and the animal data converge on a single coherent model that the authors describe as the macrophage–CXCL10–CXCR3–ISR axis — a signaling relay that translates inflammation into metastatic competence.

What makes the finding conceptually significant is how it bridges two grand themes in cancer biology that have often been studied in isolation. On one side is inflammation: the long-standing observation that tumors are wounds that never heal, festering in a soup of cytokines and immune cells whose net effect can be pro-tumor. On the other side is cell-intrinsic stress biology: the internal machinery by which individual cancer cells adapt, survive and change identity. By showing that a macrophage-derived chemokine directly engages a core cellular stress pathway to unlock metastatic behavior, the study draws a straight mechanistic line between the immune microenvironment and the plasticity of the tumor cell itself. It suggests that some of the aggressiveness of triple-negative breast cancer is not written into the cancer cells’ own mutations alone, but is coached into them by their inflammatory surroundings.

There are also therapeutic implications, and they are potentially substantial. Each node of the identified axis offers a distinct point of intervention. Inhibiting the ISR in tumor cells, antagonizing CXCR3 with targeted drugs, or neutralizing CXCL10 could each, in principle, sever the signal that converts inflammation into invasion. The finding may also help refine immunotherapy strategies: in tumors dominated by inflammatory macrophages, merely reactivating anti-cancer T cells may not suffice if macrophages are simultaneously priming tumor cells for dissemination. Interventions that reprogram or deplete pro-metastatic macrophages could complement existing immune checkpoint approaches. The authors caution, as with any preclinical discovery, that the road from mouse models and cell culture to safe, effective clinical protocols is long, but they frame the axis explicitly as a potential node for therapeutic intervention, and the pharmacological tools to test that proposition already exist in early development.

For the roughly 10 to 15 percent of breast cancer patients diagnosed with the triple-negative subtype, such prospects matter enormously. The disease disproportionately affects younger women and carries a higher burden in certain populations, and metastatic recurrence — the process this study illuminates — remains the leading cause of death. A molecular signature combining ISR activation and macrophage infiltration could also serve as a prognostic marker, helping clinicians identify which patients harbor tumors primed for spread and might benefit most from intensified surveillance or adjuvant strategies. The research was supported by the Italian Ministry of University and Research, AIRC, the Italian Ministry of Health and the European Union’s NextGenerationEU program, and the authors declare no competing interests. As the field moves toward testing ISR and chemokine-axis inhibitors in solid tumors, this study provides both the rationale and the map: a precise, testable circuit through which the immune system’s own inflammatory soldiers are co-opted to arm the enemy.

Subject of Research: How inflammatory macrophage-derived CXCL10 activates the Integrated Stress Response in triple-negative breast cancer cells to drive metastasis.

Article Title: Inflammatory macrophages promote metastatic potential in Triple-negative Breast Cancer through Integrated Stress Response signaling

Article References: Crippa, M., Salemme, V., Chauhan, J., Colombo, E., Loffreda, A., Lamolinara, A., Cardella, C., Leone, M., Licari, E., Gaviraghi, M., Genova, F., Anselmo, A., Mazza, D., Iezzi, M., R Goding, C., Defilippi, P., Tacchetti, C., & Falletta, P. (2026). Inflammatory macrophages promote metastatic potential in Triple-negative Breast Cancer through Integrated Stress Response signaling. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03821-4

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03821-4

Keywords: triple-negative breast cancer, macrophages, integrated stress response, CXCL10, CXCR3, metastasis, tumor microenvironment, inflammation, cancer research, immunotherapy, tumor-associated macrophages, Inflammatory

High-grade serous ovarian cancer remains a formidable clinical challenge, largely due to its propensity for resistance to conventional chemotherapy and its ability to sculpt an immunosuppressive tumor microenvironment. This hostile milieu stifles the body’s natural immune defenses and has rendered many immunotherapeutic approaches relatively ineffective. Immune checkpoint inhibitors, which have revolutionized treatment in cancers such as melanoma and lung carcinoma, have yet to achieve comparable success in ovarian cancer, underscoring an urgent need for innovative strategies that alter the tumor landscape to favor immune activation.

The team’s research revealed that by pharmacologically inhibiting FAK activity within ovarian cancer cells, these tumors begin to secrete extracellular vesicles—nano-scale particles—that are enriched with omega-3 fatty acids. Omega-3 fatty acids, widely recognized for their anti-inflammatory properties in systemic physiology, assume a novel role here as signaling mediators within the tumor microenvironment. These vesicles are subsequently internalized by macrophages, versatile immune cells that can adopt either pro-tumor or anti-tumor phenotypes depending on the contextual signals they receive.

Upon uptake of the omega-3-laden vesicles, macrophages undergo a profound phenotypic reprogramming, shifting from an immunosuppressive state to an activated anti-tumor mode. This transformation is marked by the macrophages’ secretion of the chemokine CXCL13, a potent attractant of tertiary lymphoid structures (TLS). TLS are ectopic immune cell aggregates that resemble lymph nodes and function as immunological hubs, orchestrating robust and localized anti-cancer responses. Previous clinical correlations have identified the presence of TLS within tumors as a biomarker for favorable patient prognosis and heightened responsiveness to immunotherapy.

Critically, this mechanistic insight was substantiated in preclinical murine models where a combinatorial treatment regimen—consisting of a FAK inhibitor, low-dose chemotherapy, and immunotherapy—was employed. The therapeutic synergy not only curtailed tumor progression but also facilitated increased infiltration of immune effector cells, culminating in extended overall survival. These findings substantiate the premise that disrupting FAK signaling interrupts the immunosuppressive feedback loop commonly exploited by ovarian tumors, thereby restoring immune competency within the tumor microenvironment.

The implications of these findings extend beyond the biochemical and cellular level, offering a tangible translational pathway. FAK inhibitors are currently under clinical evaluation, and this study provides compelling rationale to incorporate these agents alongside chemo-immunotherapy regimens. This integrated approach seeks to convert the ovarian tumor milieu from one of immunological dormancy and tolerance into an inflamed and immunostimulatory state, thereby potentially overcoming the entrenched resistance mechanisms that have long impeded therapeutic success.

Moreover, the identification of a lipid-based intercellular communication axis between tumor cells and macrophages introduces an unexplored dimension of tumor immunology. The selective packaging of omega-3 fatty acids within extracellular vesicles and their subsequent role in immune modulation offers a rich vein of scientific inquiry, with potential applications not only in ovarian cancer but also across a spectrum of malignancies characterized by immune evasion.

Institutions such as UC San Diego’s Moores Cancer Center are now poised to lead future investigations that refine these therapeutic strategies. The elucidation of this pathway underscores the importance of a multidimensional approach to cancer therapy, one that integrates molecular targeting with immunomodulation and traditional cytotoxic modalities. This integrative strategy exemplifies the ongoing evolution of precision oncology designed to enhance patient survival and quality of life.

The foundational study was spearheaded by Dr. David D. Schlaepfer, a respected figure in reproductive sciences and oncology, whose collaborative efforts with immunobiologists at Sanford Burnham Prebys Medical Discovery Institute underscore the multidisciplinary nature intrinsic to such complex biomedical research. Supported by prestigious institutions including the National Institutes of Health and the National Science Foundation, the work stands as a testament to rigorous scientific inquiry backed by robust funding frameworks.

Published in the esteemed journal Cell Reports, the research not only charts new territory in ovarian cancer biology but also establishes a preclinical blueprint for clinical translation. As the oncology community eagerly anticipates the results of forthcoming clinical trials examining FAK inhibitors’ efficacy, this study provides a well-founded scientific cornerstone advocating for combination regimens that harness immune system reactivation.

In essence, the revelation that inhibition of focal adhesion kinase can convert ovarian tumors from immune-excluding fortresses into vulnerable targets for immune destruction heralds a promising new era in cancer therapy. By harnessing the power of omega-3 fatty acid-mediated intercellular communication and macrophage re-education, these insights provide renewed hope for patients battling one of the most intractable forms of cancer.

Subject of Research: Immune system reprogramming in ovarian cancer through focal adhesion kinase inhibition.

Article Title: Not provided.

News Publication Date: Not provided.

Web References:

• Cell Reports Publication
• DOI: 10.1016/j.celrep.2026.117009

References:

• The original study as published in Cell Reports by UC San Diego research teams and collaborators.

Image Credits: UC San Diego Health Sciences

Keywords: Ovarian cancer, Focal adhesion kinase (FAK), Immunotherapy, Macrophage reprogramming, Omega-3 fatty acids, Tumor microenvironment, Tertiary lymphoid structures, CXCL13, Extracellular vesicles, Chemokines, Immune activation, Cancer immunology